Thrombotic complications of erythropoiesis-stimulating agents

Seminars in Thrombosis and Hemostasis
Giuseppe LippiEmmanuel J Favaloro

Abstract

The synthesis of erythropoiesis-stimulating agents (ESAs), especially recombinant human erythropoietin, has provided a new therapeutic option for the treatment of patients with various forms of anemia, including that of chronic renal disease, malignancy, hematologic disorders, prematurity, and acquired immune deficiency syndrome. These agents are effective in improving the hematologic response and reducing the need for red blood cells transfusion, and they also appear to have a positive effect on some health-related quality-of-life indicators. The incidence of side effects and survival, however, remains highly uncertain, and several studies have recently highlighted the problem of an increased trend of tumor progression, mortality and thrombotic complications, especially venous thromboembolism, in patients undergoing therapy with ESAs. Specifically, the biological background underlying the prothrombotic effects of ESAs is multifaceted (polycythemia/hyperviscosity syndrome, hypertension, thrombocytosis, platelet hyperactivity, activation of blood coagulation) and context dependent, and it most likely requires the presence of additional prothrombotic factors. Nevertheless, this clinical and biological evidence supports the hypoth...Continue Reading

Citations

Jul 3, 2013·Blood Reviews·Massimo Franchini, Pier Mannuccio Mannucci
Jan 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PetrelliS Barni
Feb 9, 2013·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Maurizio ZangariJosef T Prchal
Apr 13, 2011·Seminars in Dialysis·Andres F CarrionPaul Martin
Jul 25, 2013·Critical Reviews in Oncogenesis·Kristina VanderWallAlan Lichtenstein
Sep 23, 2014·Thrombosis Research·Marit M SuttorpFriedo W Dekker
Jan 24, 2015·Thrombosis Research·Yosef KalishDavid Varon
Dec 25, 2012·Gynecologic Oncology·Koji MatsuoLynda D Roman
Feb 25, 2011·Transfusion Medicine Reviews·Eleftherios C Vamvakas
Dec 7, 2011·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Jan Hendrik Duedal RölfingCody Bünger
Oct 24, 2012·Anemia·Antonio Macciò, Clelia Madeddu
Aug 21, 2013·European Journal of Heart Failure·B Daan WestenbrinkPeter van der Meer
Oct 22, 2014·Transfusion·Joseph A Posluszny, Lena M Napolitano
Jul 2, 2016·Expert Opinion on Drug Safety·Massimo Franchini, Pier Mannuccio Mannucci
Jan 20, 2017·Expert Opinion on Drug Safety·Massimo Franchini, Pier Mannuccio Mannucci
May 29, 2016·Journal of Child Neurology·Kye Hee ChoMinYoung Kim
Jun 16, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·A GirolamiB Girolami
Apr 5, 2012·Circulation·Richard H White
Jun 20, 2020·Blood·Jeffrey A Gilreath, George M Rodgers
Sep 13, 2021·Journal of Clinical Pharmacology·Chien-Tung WuJung-Nien Lai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.